secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2026-07-02T12:00:40+00:00
Accession:  0001193125-26-293485
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August
--------------------------------------------------------------------------------

- Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).
- Company expects to report topline data in August 2026; database lock and statistical analysis underway.
- Trial evaluates TNX-103 (oral levosimendan) in PH-HFpEF; enrollment of >230 patients completed March 2026.
- BSSR in Dec 2025 showed >90% power to detect 25m change in 6MWD primary endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/0001193125-26-293485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/d20457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-293485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer